Data / Drug companies / Hubei JXBio Pharmaceutical Co.,Ltd
Hubei JXBio Pharmaceutical Co.,Ltd: 9 products in the FDA NDC directory, labeler code 76617
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Hubei JXBio Pharmaceutical Co.,Ltd (labeler code 76617) lists 9 products in the FDA National Drug Code Directory. By type: 9 bulk ingredients. Its main marketing category is bulk ingredients. The newest product started marketing on October 26, 2026.
The request: Watch Hubei JXBio Pharmaceutical Co.,Ltd (FDA labeler code 76617): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 76617
- Products in commercial distribution
- 9
- Packages
- 37
- Finished drugs by generic name
- 0
- Prescription products
- 0
- Over the counter products
- 0
- Started marketing in the last 12 months
- 4
- Earliest marketing start
- April 24, 2020
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Bulk ingredients | 5 | 55.6% |
| Bulk ingredients for compounding | 4 | 44.4% |
Products by type
| Type | Products | Share |
|---|---|---|
| Bulk ingredients | 9 | 100% |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Powder | 9 | 100% |
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Atosiban acetate | 76617-008 | Powder | Bulk ingredients | October 26, 2026 |
| Octreotide acetate | 76617-007 | Powder | Bulk ingredients | October 15, 2026 |
| Leuprorelin acetate | 76617-006 | Powder | Bulk ingredients | January 1, 2026 |
| Sermorelin acetate | 76617-005 | Powder | Bulk ingredients for compounding | December 16, 2025 |
| Semaglutide | 76617-003 | Powder | Bulk ingredients | January 9, 2025 |
| Liraglutide | 76617-002 | Powder | Bulk ingredients for compounding | March 14, 2024 |
| Tirzepatide | 76617-020 | Powder | Bulk ingredients for compounding | December 5, 2022 |
| Semaglutide | 76617-001 | Powder | Bulk ingredients for compounding | November 17, 2022 |
| Oxytocin | 76617-011 | Powder | Bulk ingredients | April 24, 2020 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.